 | | Vol. 12.42 – 18 November, 2021 |
| |
|
|
| Researchers showed that dietary palmitic acid, but not oleic acid or linoleic acid, promoted metastasis in oral carcinomas and melanoma in mice. Tumor-associated Schwann cells secreted a specialized proregenerative ECM, the ablation of which inhibited metastasis initiation.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported a family of synthetic hydrogels that promoted extensive organoid morphogenesis through dynamic rearrangements mediated by reversible hydrogen bonding.
[Nature Materials] |
|
|
|
| Scientists reported that recently identified tubular clathrin/AP-2 lattices, a subset of clathrin-coated structures (CCSs) that pinched collagen fibers, mechanically controlled directed migration along fibers decorated with ligands of CCS cargoes in 3D environments.
[Science Advances] |
|
|
|
| Researchers developed fibrous hydrogel assemblies that were stabilized with photocrosslinking and displayed fiber density–dependent strain-responsive properties.
[Science Advances] |
|
|
|
| The authors discovered that proteoglycan Agrin was enriched within the early wound-microenvironment and was indispensable for efficient healing.
[Nature Communications] |
|
|
|
| Scientists found that ensheathing glia were polarized with a basolateral plasma membrane rich in phosphatidylinositol-(3,4,5)-triphosphate and the Na+/K+-ATPase Nervana2 that abuted an ECM formed at neuropil-cortex interface.
[Nature Communications] |
|
|
|
| Investigators established an alginate hydrogel system with constant stiffness and tunable stress relaxation rate, which was a key parameter for the viscoelastic property of the material.
[Biomaterials] |
|
|
|
| Researchers revealed that delivery of miR-122 was associated with the downregulation of key genes involved in metastatic and cancer inflammation pathways, including several pro-inflammatory factors, matrix metalloproteinases, and other ECM degradation enzymes.
[Cancer Research] |
|
|
|
| Based on an analysis of patient datasets, the authors found that SIX1 was upregulated in human tumor tissues and that its expression levels were negatively correlated with immune cell infiltration in the tumor microenvironment and the overall survival rates of cancer patients.
[Cellular & Molecular Immunology] |
|
|
|
| Scientists reported that mammary epithelial-specific disruption of β1 integrin in a murine model of Luminal B human breast cancer drastically impaired tumor growth with proliferation block, apoptosis induction and cellular senescence.
[Oncogene] |
|
|
|
| To enable tumor-localized immunotherapy following intravenous administration, investigators chemically conjugated a polyspecific integrin-binding peptide (PIP) to an immunostimulant to generate a tumor-targeted immunomodulatory agent, referred to as PIP-CpG.
[Cell Chemical Biology] |
|
|
|
| Researchers examined the relationship between the tumor microenvironment and the clinical efficacy of neoadjuvant chemotherapy in patients with cT2-4aN0M0 bladder cancer using multiplex fluorescence immunohistochemistry.
[British Journal of Cancer] |
|
|
|
| Inhibition of matrix metalloprotease 2 (MMP2) restricted functional transfer of hepatic miRNAs across the hepatic and non-hepatic cell boundaries and by targeting MMP2. Scientists could reduce the innate immune response in mammalian liver by preventing intra-tissue miR-122 transfer.
[iScience] |
|
|
|
|
| The authors provide information on the immune microenvironments underlying the response or resistance of hepatocellular carcinoma to immunotherapies.
[Nature Reviews Clinical Oncology] |
|
|
|
| Scientists comprehensively discuss the underlying regulatory mechanisms of exosomes in human diseases.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators review the mechanisms involved in the generation and biological role of myeloid cell-derived oxidized lipids in cancer.
[Cancer Research] |
|
|
|
|
| iBio, Inc. announced a research collaboration with the University of Texas (UT) Southwestern Medical Center to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program.
[iBio, Inc.] |
|
|
|
| Patient dosing has begun in a Phase Ib/IIa clinical trial to evaluate the safety, tolerability and pharmacologic activity of CEND-1, an investigational drug that modifies the tumor microenvironment, in pancreatic, appendiceal and colon cancers in collaboration with the University of Kansas Cancer Center.
[Cend Therapeutics, Inc. (GlobeNewswire, Inc.)] |
|
|
|
|
| November 29 – December 1, 2021
Virtual |
|
|
|
|
|
| | German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany |
|
|
|
| Weill Cornell Medical College – New York, New York, United States |
|
|
|
| | Uppsala University – Uppsala, Sweden |
|
|
|
| | Oregon Health & Science University – Portland, Oregon, United States |
|
|
|
| | The University of Sheffield – Sheffield, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
